<div id="readability-page-1"><h3>President's Day Sale - 70% Off</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>CStone Pharmaceuticals ( (HK:2616) ) just unveiled an update. CStone Pharmaceuticals announced that the UK Medicines and Healthcare products Regulatory Agency has approved a new indication for its anti-PD-L1 antibody sugemalimab as monotherapy for adult patients with unresectable stage III non-small cell lung cancer whose disease has not progressed after platinum-based chemoradiotherapy. The decision, supported by the Phase III GEMSTONE-301 trial showing significant progression-free and overall survival benefits, marks the second sugemalimab indication in the UK and strengthens the drug’s position as one of only two PD-(L) 1 antibodies approved for stage III NSCLC in Europe. With commercialization partnerships now covering more than 60 countries and multiple inclusions in national reimbursement systems, CStone is accelerating the global rollout of sugemalimab and enhancing its international oncology presence. The company plans further regulatory filings for additional indications, including gastric cancer and esophageal squamous cell carcinoma, which could broaden its revenue base and reinforce its competitive standing in the global immuno-oncology market. The most recent analyst rating on (HK:2616) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page. More about CStone Pharmaceuticals CStone Pharmaceuticals is a China-based biopharmaceutical company focused on the development and commercialization of innovative oncology therapies. Its pipeline centers on immuno-oncology drugs, including the anti-PD-L1 monoclonal antibody sugemalimab, with a growing commercial footprint across Europe, the Middle East, Africa, Latin America and China. Average Trading Volume: 8,370,213 Technical Sentiment Signal: Strong Buy Current Market Cap: HK$8.59B See more insights into 2616 stock on TipRanks’ Stock Analysis page.</div>

513060

159859

159102

CStone Pharmaceuticals has received UK approval for its lung cancer drug, sugemalimab, as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer. This marks the second indication for the drug in the UK, supported by positive results from the Phase III GEMSTONE-301 trial. CStone is expanding its global presence with commercialization partnerships in over 60 countries and plans further regulatory filings for additional indications. The current analyst rating for CStone's stock (HK:2616) is a Sell with a price target of HK$5.00.

Tip Ranks

Bosera Hang Seng Health Care ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Huaan Hang Seng Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

CSTONE PHARMA-B

Penghua SSE STAR Biology and Medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Guotai CSI Bio-medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab